ALTO-100
Phase 2Small molecule
ALTO-100 is one of 49 small molecule programs targeting Bipolar Disorder. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
192 competitors in Bipolar Disorder
#DrugCompanyPhaseTrials
1Depacon
AbbViePhase 3
Depakote
AbbViePhase 3
Depakote
AbbViePhase 3
Lexapro
AbbViePhase 3
Robitussin
PfizerPhase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Rescue
Merck & Co.Phase 3
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALTO-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAlto Neuroscience